Title

Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy

Document Type

Article

Peer Reviewed

1

Publication Date

8-1-2007

NLM Title Abbreviation

Lancet Oncol

Journal/Book/Conference Title

The lancet oncology

PubMed ID

17679084

DOI of Published Version

10.1016/S1470-2045(07)70242-5

Start Page

738

End Page

743

Abstract

An expanding knowledge of the signalling pathways involved in the cell cycle has led to great improvements in the understanding of the molecular events involved in carcinogenesis. The past decade has seen substantial advances with the introduction of several classes of targeted therapeutics for the treatment of various cancers and autoimmune disorders. However, the question arises as to whether pregnant women can take advantage of these new treatments in view of the potential risks to the fetus. Published work suggests that biological agents, like traditional treatments, have the potential to affect the fetus, and should, therefore, be used with caution during pregnancy. However, when targeted treatment is clearly indicated the magnitude of the risk to the fetus might not reach that of standard chemotherapy. In circumstances where better alternative treatments do not exist, or where failure to use targeted treatments would result in suboptimum patient care or survival, the risk-benefit analysis might favour the use of potentially effective molecular treatment during pregnancy.

Keywords

Antibodies, Monoclonal/therapeutic use, Antineoplastic Agents/therapeutic use, Female, Humans, Neoplasms/immunology/metabolism/therapy, Pregnancy, Pregnancy Complications, Neoplastic/immunology/metabolism/therapy, Pregnant Women, Protein Kinase Inhibitors/antagonists & inhibitors

Published Article/Book Citation

The lancet oncology (2007) 8:8, pp. 738-743.

This document is currently not available here.

Share

COinS
 

URL

https://ir.uiowa.edu/obgyn_pubs/44